AXSOME THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

04 فبراير 2025 10:19:52 بحسب NetDania Notify

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

31 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

30 يناير 2025 15:45:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

30 يناير 2025 09:45:15 بحسب NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

27 يناير 2025 10:08:34 بحسب NetDania Notify

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

22 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

13 يناير 2025 07:00:01 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

30 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

26 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

13 نوفمبر 2024 09:49:44 بحسب NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

12 نوفمبر 2024 10:02:19 بحسب NetDania Notify

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

08 نوفمبر 2024 07:00:28 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

29 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

15 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

24 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

04 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in Investor Conferences in September

27 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

21 أغسطس 2024 07:00:39 بحسب Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

05 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire